| Oct 29 |
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
|
| Oct 28 |
Incyte Q3 2024 Earnings Preview
|
| Oct 24 |
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
|
| Oct 22 |
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
|
| Oct 15 |
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
|
| Oct 10 |
A Look Into Incyte Inc's Price Over Earnings
|
| Oct 10 |
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
|
| Oct 8 |
GMAB or INCY: Which Is the Better Value Stock Right Now?
|
| Oct 8 |
Incyte to Report Third Quarter Financial Results
|
| Oct 3 |
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
